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Summary 
Crystallographic studies of ligands bound to biological macromolecules (proteins and 
nucleic acids) represent an important source of information concerning drug-target 
interactions, providing atomic level insights into the physical chemistry of complex 
formation between macromolecules and ligands. Of the more than 115,000 entries 
extant in the Protein Data Bank archive, ~75% include at least one non-polymeric ligand. 
Ligand geometrical and stereochemical quality, the suitability of ligand models for in 
silico drug discovery/design, and the goodness-of-fit of ligand models to electron density 
maps vary widely across the archive. We describe the proceedings and conclusions 
from the first Worldwide Protein Data Bank/Cambridge Crystallographic Data 
Centre/Drug Design Data Resource (wwPDB/CCDC/D3R) Ligand Validation Workshop 
held at the Research Collaboratory for Structural Bioinformatics at Rutgers University on 
July 30-31, 2015. Experts in protein crystallography from academe and industry came 
together with non-profit and for-profit software providers for crystallography and with 
experts in computational chemistry and data archiving to discuss and make 
recommendations on best practices, as framed by a series of questions central to 
structural studies of macromolecule-ligand complexes. What data concerning bound 
ligands should be archived in the Protein Data Bank? How should the ligands be best 
represented? How should structural models of macromolecule-ligand complexes be 
validated? What supplementary information should accompany publications of structural 
studies of biological macromolecules? Consensus recommendations on best practices 
developed in response to each of these questions are provided, together with some 
details regarding implementation.  Important issues addressed but not resolved at the 
workshop are also enumerated. 
1 Background 
The Worldwide Protein Data Bank (wwPDB; wwpdb.org), the Cambridge 
Crystallographic Data Center (CCDC; www.ccdc.cam.ac.uk), and the Drug Design Data 
Resource (D3R; www.drugdesigndata.org) co-organized a Ligand Validation Workshop 
on July 30-31 2015 at Rutgers University. The workshop brought together academic and 
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industrial protein crystallographers, providers of software for crystallography, 
computational chemists, and experts in data archiving. More than 50 participants from 
more than 40 organizations discussed and made recommendations on best practices for 
structural studies of macromolecule-ligand complexes and archiving of the resulting 
information. 
1.1 Protein Data Bank (PDB) and Historical Context for the Workshop 
The Protein Data Bank (PDB) was established in 1971 with just seven X-ray 
crystallographic structures of proteins as the first open access digital resource in the 
biological sciences (Protein Data Bank, 1971). In February 2016, some 44 years later, 
this sui generis global archive holds more than 115,000 experimentally determined 3D 
structural models of biological macromolecules and their complexes with a wide variety 
of ligands. In addition, descriptions of the chemistry of biopolymers and ligands are 
collected, as are metadata describing sample preparation, experimental methodology, 
structural model building and refinement statistics, literature references, etc. PDB data 
are made freely available without restrictions on usage. The vast majority of data in the 
PDB (~90%) come from X-ray, neutron, and combined X-ray/neutron crystallography, 
with the remainder contributed by two newer 3D structure determination methods: 
nuclear magnetic resonance (NMR) spectroscopy and electron microscopy (3DEM).  
 
Considerable effort has gone into understanding how best to curate structural models 
and primary experimental data from X-ray, NMR, and 3DEM. Over the past decade, the 
Worldwide Protein Data Bank (wwPDB; the global organization responsible for 
managing the PDB archive; wwpdb.org) (Berman et al., 2003) has formed expert, 
method-specific Validation Task Forces to identify which experimental data and 
metadata from each structure determination method should be archived and how these 
data and the atomic level structural models therefrom should be validated. Initially, the 
wwPDB X-ray Validation Task Force (VTF) made recommendations on how to best 
validate crystallographic data (Read et al., 2011). These initial recommendations have 
been implemented as a validation pipeline used within the wwPDB Deposition and 
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Annotation (D&A) system. A wwPDB Validation Report accompanies every PDB 
deposition (ftp://ftp.wwpdb.org/pub/pdb/validation_reports/). Preliminary 
recommendations have also been made by wwPDB VTFs for NMR (Montelione et al., 
2013) and 3DEM (Henderson et al., 2012). Implementation of NMR and 3DEM VTF 
recommendations within the wwPDB D&A validation pipeline is currently underway.  It is 
anticipated that additional validation measures will be implemented within the wwPDB 
D&A system as new methods are developed and more experience is gained with 
existing procedures. 
 
1.2 Crystallographic Data in the PDB 
For structural models determined via X-ray, neutron, and combined X ray/neutron 
crystallography methods, together with those determined using electron diffraction from 
2D crystals, deposition of experimental data (i.e., diffracted intensities or structure factor 
amplitudes) into the PDB has been mandatory since 2008 
(http://www.wwpdb.org/news/news?year=2007#29-November-2007). Validation against 
deposited structure factor amplitudes is carried out using procedures recommended by 
the wwPDB X-ray VTF (Read et al., 2011). wwPDB Validation Reports include graphical 
summaries of the quality of the overall structural model and residue-specific features. 
Detailed assessments of various aspects of the structural model, such as agreement 
with experimental data and chemical expectations, are also provided. In the near future, 
unmerged intensities will also be collected during PDB deposition, thereby enabling 
additional validation. 
 
1.3 Chemical Component Dictionary  
The Chemical Component Dictionary (CCD) was originally developed (Feng et al., 2004) 
to provide a more expressive alternative to the early PDB ligand descriptions, which 
were based purely on atom connectivity records. The CCD embraced the data 
representation for chemical components developed for the Macromolecular 
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Crystallographic Information Framework or mmCIF data dictionary (Fitzgerald et al., 
2005). Following a major wwPDB undertaking to standardize nomenclature concluded in 
2007 (Henrick et al., 2008), the global organization adopted a common dictionary of 
chemical definitions. The current Chemical Component Dictionary (Westbrook et al., 
2015) is an extended reference file describing all polymer components and small 
molecules found in PDB archival entries. This dictionary contains detailed chemical 
descriptions for standard and modified amino acids/nucleotides, small molecule ligands, 
and solvent/solute molecules. Each chemical definition includes descriptions of chemical 
properties, such as stereochemical assignments, chemical descriptors [SMILES 
(Weininger, 1988), InChI, and InChIKeys (Heller et al., 2013)], and systematic chemical 
names. A set of atomic model coordinates from a selected experimental entry and a 
computed set of ideal atomic coordinates are provided for each entry in the CCD. 
Hydrogen atoms are computationally added to the experimental coordinates and 
unobserved heavy atoms, such as leaving groups specified by Depositors, are added to 
the ideal coordinates if they are not explicitly modeled in the experimental entry. 
Computed ideal coordinates are obtained from the software tools Corina (Gasteiger et 
al., 1990) or OpenEye/Omega (Hawkins et al., 2010). Cahn-Ingold-Prelog (CIP) 
stereochemical assignments (Cahn et al., 1966) and aromatic annotations are 
documented for each atom present in each CCD entry. The dictionary is organized by 
the 3-character alphanumeric code that the wwPDB assigns to each chemical 
component, and updated with each weekly release of the PDB archive (Sen et al., 
2014). 
 
A related PDB archive chemical reference dictionary is the Biologically Interesting 
molecule Reference Dictionary (BIRD) (Dutta et al., 2014; Young et al., 2013), which 
contains information about peptide-like antibiotic and inhibitor molecules present in the 
PDB archive.  BIRD entries include molecular weight and chemical formula, polymer 
sequence and connectivity, descriptions of structural features and functional 
classification, natural source, and external references to corresponding UniProt (UniProt 
Consortium, 2015) or Norine (Caboche et al., 2008) reference sequences. 
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A BIRD molecule may be represented in a PDB archival entry as a polymer with 
sequence information or as a single ligand with chemical information. The preferred 
representation is specified in the BIRD file, with a representative PDB ID code. All PDB 
entries containing the same BIRD molecule or its analogue(s) are represented uniformly. 
An important feature of BIRD is to provide dual representation–both sequence and 
chemical information is provided, regardless of whether the molecule is represented as a 
polymer or as a ligand in the PDB archive. 
 
1.4 Current Validation of Macromolecule-Ligand Complexes 
The initial recommendations of the wwPDB X-ray VTF (Read et al., 2011) have been 
implemented in a software pipeline (Gore et al., 2012) embedded within the wwPDB 
D&A system. Officially watermarked wwPDB Validation Reports are provided to PDB 
contributors at the time of deposition.  An increasing number of journals require that 
these reports accompany manuscripts reporting structural studies of biological 
macromolecules.  Structural biologists can obtain a similar report using the wwPDB 
Validation Server (http://wwpdb-validation.wwpdb.org/) prior to deposition. For ligands, 
the wwPDB Validation Report includes both geometrical and model fit diagnostic 
information. Bond lengths and angles, acyclic torsion angles, and ring systems are 
assessed (Bruno et al., 2004) by comparison with preferred molecular geometries 
derived from high-quality, small-molecule structures in the Cambridge Structural 
Database (CSD) (Groom and Allen, 2014).  
 
A Z-score is calculated for every bond length and bond angle in each ligand. Individual 
bond lengths or bond angles with a Z-score magnitude>2 are highlighted. The root-
mean-square value of the Z-scores (RMSZ) of bond lengths (or angles) is calculated for 
the entire molecule.  The EDS software (Kleywegt et al., 2004) is used to calculate 
density maps from deposited atomic coordinates and experimental data, which are 
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compared to idealized map density with the difference reported as a Real Space R-value 
(RSR). This analysis is performed on an individual ligand basis. A Local Ligand Density 
Fit (LLDF; for a description of this calculation see 
http://www.wwpdb.org/validation/ValidationPDFNotes.html) then compares the RSR of a 
molecule to the mean and standard deviation of RSR for the neighbouring polymeric 
standard amino acids and/or nucleotides. Minimum, median, 95th percentile and 
maximum atomic displacement parameters (isotropic B-values) for all atoms in the 
molecule are presented along with the number of atoms in the ligand molecule with 
occupancies of less than 0.9.  
 
1.5 Quality of Macromolecule-Ligand Complexes in the PDB 
Of the more than 115,000 entries in the PDB today, some 76% include at least one non-
polymeric small molecule ligand. While some of these ligands are almost certainly 
crystallization solutes, many were intentionally included in the experimental sample or 
co-purified with the structure determination target and are of considerable biological, 
biochemical, or medical interest. Recently published review articles assessing the quality 
of macromolecule-ligand complexes in the PDB can be usefully broken down into three 
categories, including  
i) assessments of geometrical and stereochemical quality (Liebeschuetz et al., 2012; 
Sehnal et al., 2015; Zheng et al., 2014);  
ii) the suitability of ligand models for in silico drug discovery/design (Davis et al., 2008; 
Smart and Bricogne, 2015; Warren et al., 2012); and  
iii) general issues with ligand atomic model fit to the electron density map (Malde and 
Mark, 2011; Pozharski et al., 2013; Sitzmann et al., 2012; Weichenberger et al., 2013).  
 
It has been emphasized by some that a non-negligible number of structural biologists err 
by interpreting weak density map features as indicating the presence of a bound small 
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molecule that has been included in the crystallization process or soaked into a pre-
formed crystal [e.g., (Rupp, 2010)]. Current validation and journal refereeing policies and 
practices do not always prevent such cases from entering either the PDB archive or the 
scientific literature. Other explanations of problems with macromolecule-ligand 
complexes in the PDB include the following:  
i) some ligands undergo chemical transformation upon binding, which may not be 
reflected in the atomic model used for refinement;  
ii) the ligand may be present, but was modeled incorrectly or refinement was performed 
with incorrect restraint targets; and  
iii) the ligand does bind, but the experimentalist does not provide an accurate chemical 
descriptor. 
 
1.6 Workshop Format and Charge to Participants 
Catherine E. Peishoff (GlaxoSmithKline) gave the keynote address emphasizing the 
value of atomic level structural information for pharmaceutical discovery research and 
the growing opportunities for pre-competitive engagement and data sharing.  She 
stressed the importance of data and structural model quality and the need for data 
archived in the PDB to be fit for purpose. Finally, she suggested a move away from the 
historical view of the PDB as an archival database towards an increased emphasis on 
data provisioning, which would shift the focus from any single structure to the structures 
as a collective. Increased attention to data standards, governance, and quality, together 
with improving tools to analyze the collective data, will significantly help researchers 
derive insight from this valuable scientific resource.  
 
Stephen K. Burley (RCSB Protein Data Bank) and Gerard J. Kleywegt (Protein Data 
Bank in Europe) then introduced the workshop rationale/objectives and charged the 
participants with dividing among smaller breakout groups and addressing five questions 
regarding best practices for macromolecule-ligand complex data deposition and 
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validation and journal editorial, refereeing, and publication practices. Breakout group 
members were selected on the bases of interest and expertise as follows: Group A, 
Academic and Industrial Crystallographers; Group B, Crystallographic Software 
Specialists; Group C, Computational Chemistry Software Specialists; and Group D, 
Academic and Industrial Crystallographers. After lengthy and lively discussions, the four 
breakout groups reconvened to report their findings and develop consensus 
recommendations. Each group independently approached the same set of questions. 
 
2 Workshop Deliberations and Recommendations 
2.1 Charge to the Workshop 
To address some of the myriad challenges facing PDB Depositors and Users and 
Editors and Referees of scientific journals that publish the results of structural studies of 
macromolecule-ligand complexes, the community stakeholders assembled at Rutgers 
considered the following five questions:  
1) What are current best practices for selecting an initial ligand atomic model(s) for co-
crystal structure refinement against diffraction data? 
 
2) What are current best practices for validating the ligand(s) coming from such a co-crystal 
structure refinement? 
 
3) What new data pertaining to co-crystal structures should be required for PDB depositions 
going forward? 
 
4) What information should accompany journal submissions reporting co-crystal structure 
determinations? What supplementary materials should accompany publication of co-
crystal structure determinations? 
 
5) What do you recommend be done with existing co-crystal structures in the PDB archive? 
 
Towards the close of the meeting, the groups reconvened to compare findings, identify 
areas of commonality and divergence, and determine how best to move forward. This 
document reflects the resulting consensus. 
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2.2 Workshop Recommendations 
Recommended Best Practices for PDB Archive Deposition of Co-crystal Structure 
Data: 
Depositors should  
1. Provide unambiguous chemical definitions for ligands present in the crystal 
mother liquor and in the refined structural model, including hydrogen atoms and 
covalent modifications. 
2. Provide the geometry of the starting model of the refined ligand(s), ligand-related 
refinement restraints, and their provenance. 
3. Use the PDBx/mmCIF dictionary _atom_site.calc_flag to identify non-
experimentally modeled atoms. Non-experimentally modeled atoms, for the 
purposes of this recommendation, are defined as those atoms whose positions 
are not adequately localized by experimental data (e.g., electron density map) to 
be assigned (x,y,z) positional coordinates, but whose presence is deduced by 
chemical knowledge of the crystal content and other information. This flag will 
usually be applicable to the hydrogen atom records for ligands. It is intended for 
use as an alternative to zero occupancy, which would be a less accurate indicator 
of the status of these atoms. 
4. Provide the Fourier coefficients of the density map(s) used for ligand(s) structure 
interpretation. 
5. Identify 
a) any ligand that is a focus of the study, where appropriate; 
b) any other biologically important ligand(s);  
c) adventitiously bound ligand(s) (i.e., co-purified) and ligands added for 
experimental convenience (e.g., crystallization additives or cryo-protectants); and 
d) the experimental method (crystal soaking versus co-crystallization) for (a) and 
(b).  
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6. As applicable, communicate other experimental findings, judgment calls, and 
perceived ambiguities regarding tautomers and protonation states of ligands not 
determined conclusively from the crystallographic data and chemical environment 
of the ligand by either (a) using the existing alternate conformation mechanism 
with partial occupancies or (b) providing the chemical descriptions recommended 
in Item 1 above. 
7. Where appropriate, include comments explaining outliers, etc. identified in the 
wwPDB Validation Report. 
 
Recommended Best Practices for wwPDB Validation of Co-crystal Data: 
  
Building on the framework of the current wwPDB Validation Report, the following new 
items should be included: 
1. Informative images of ligand pose(s) plus nearby density map features using 
Fourier coefficients endorsed by the wwPDB X-ray VTF [e.g., 2m|Fo|-D|Fc|, 
m|Fo|-D|Fc|, and omit map (Bhat, 1988; Bhat and Cohen, 1984)] and those 
provided by the Depositor.  The presentation style in the Buster Report tool 
(Smart and Bricogne, 2015) exemplifies the diagnostic utility of such 
representations (Figure 1). 
2. Stick-figure representations of ligand(s) with non-hydrogen atom labels annotated 
with geometric validation findings. 
3. Identification of atoms modeled but not interpreted from density maps. 
4. Quality assessment metrics for each study compound and biologically important 
ligand(s). 
5. Identification of ligands capable of tautomerism or alternate protonation states 
within the pH range typical of protein crystals, nominally 4-10. 
 16 
6. The wwPDB D&A Validation pipeline should be described in full in peer-reviewed 
publications and continue to be publicly available for use in improving models 
prior to PDB archive deposition. The reference data used to calculate quality 
metrics/percentile scores should also continue to be publicly available. All the 
details describing the wwPDB Validation pipeline should be made available so 
that it can be implemented in an external environment. Specifically, details related 
to wwPDB Validation pipeline script(s), versions of the publicly available and 
commercial programs used therein, and input parameters and any other details 
necessary for reproducibility should be made public as soon as possible.  
Recommendations regarding Editorial/Refereeing/Publication Standards for Co-
crystal Structure Publications: 
 
Journals should 
 
1. Require submission of officially watermarked PDF wwPDB Validation Reports as 
Supplementary Materials accompanying manuscripts describing macromolecular 
structure determinations. 
2. Ensure that at least one of the Referees selected for manuscript review has the 
technical expertise to evaluate in full the content of the wwPDB Validation Report. 
 
2.3 Response of the wwPDB X-ray Validation Task Force 
Following the conclusion of the Workshop, the recommendations outlined herein were 
presented to the membership of the wwPDB X-ray Validation Task Force (Chair: Randy 
Read, Cambridge University) when the group reconvened at the European 
Bioinformatics Institute in November 2015. The recommendations received strong 
support from the Task Force. The wwPDB partner organizations (RCSB PDB, PDBj, 
PDBe, and BMRB) are currently developing an implementation plan for 
recommendations relating to data requirements and updates of the PDBx/mmCIF 
dictionary and will finalize the plan in due course with the benefit of further advice from 
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the Task Force and the PDBX/mmCIF Working Group (Chair: Paul Adams, Lawrence 
Berkeley Laboratory).  
 
2.4 Implementation Details 
Implementation of the recommendations regarding additional archival content will require 
extension of the PDBx/mmCIF dictionary to capture details of the starting ligand model 
and the Depositors’ identification of the role of the ligand in each study.  The 
PDBx/mmCIF Working Group (Chair: Paul Adams, Lawrence Berkeley Laboratory) is 
currently working on developing deposition standards for ligand refinement restraints 
and delivery of additional supporting data in the form of density map Fourier coefficients 
and unmerged intensities. Further extensions of the PDBx/mmCIF dictionary can be 
made as needed. With the requisite PDBx/mmCIF dictionary items in place, the wwPDB 
D&A system can be modified to ensure efficient capture of these new data during 
deposition.   
 
An enhanced version of the wwPDB Validation Report will furnish the recommended 
depictions for ligand fits to map density and the annotated stick-figure models, with 
geometrical, stereochemical, and absence annotations. Development of a summary 
indicator of ligand quality for inclusion within the wwPDB Validation Report summary 
graphic requires additional research.  
 
The wwPDB Validation Report also provides a convenient vehicle for delivering the 
recommended depictions of ligand density map to improve publication practices. Some 
scientific journals already require that wwPDB Validation Reports accompany structure 
manuscripts. Further community lobbying of Editors is needed to expand the number of 
journals requiring submission of the wwPDB Validation Report. Finally, it is incumbent on 
the scientific community that experts continue to undertake rigorous review of 
manuscripts describing structural studies of macromolecule-ligand complexes. 
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Strong sentiments expressed both in the literature [e.g., (Terwilliger and Bricogne, 
2014)] and during the workshop favored revision of the current wwPDB policy requiring 
issuance of new PDB ID codes following update of deposited atomic coordinates. 
Indeed, some Depositors report being reluctant to update atomic coordinates, because 
issuance of the new PDB ID code is thought to weaken the connection between the 
revised PDB archival entry and prior publications describing the structure. It was agreed 
that the wwPDB leadership, in consultation with the wwPDB Advisory Committee, should 
come to closure on the matter of versioning of atomic coordinates and other archival 
data as soon as possible. 
 
Binding of ligands to macromolecules can also be studied using NMR spectroscopy. 
Members of the wwPDB NMR VTF present at the workshop volunteered the services of 
their task force to develop recommendations regarding data deposition and validation 
standards for structural models of macromolecule-ligand complexes determined by 
NMR. 
 
2.5 Issues Addressed but Not Resolved at the Workshop 
Workshop participants discussed three additional topics without reaching consensus. 
    
First, some participants strongly advocated mandatory journal submission of processed 
diffraction data and atomic coordinates to accompany manuscripts describing 
crystallographic studies of biological macromolecules.  This practice is the norm for 
small-molecule crystallography publications. With the benefit of full and frank discussion, 
it was recognized that author sensitivities regarding providing primary data and atomic 
coordinates in advance of publication to reviewers, who may also be competitors, 
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precluded consensus on this matter. The wwPDB leadership in consultation with the 
wwPDB Advisory Committee will revisit this issue. 
 
Second, some participants strongly advocated mandatory PDB deposition of all-atom 
structural models, including computed positions of hydrogen atoms (properly identified 
with the _atom_site.calc_flag). As inclusion of explicit hydrogen atoms will impact the 
entire PDB archive, it was agreed that 
i) technical recommendations on this front should be made by the wwPDB X-ray 
Validation Task Force; and  
ii) wwPDB leadership, in consultation with the wwPDB Advisory Committee, should 
make further policy recommendations as necessary.  
 
 
Finally, workshop participants identified a number of challenges that will come to the fore 
once enhanced validation of macromolecule-ligand complexes already archived in the 
PDB is concluded and updated wwPDB Validation Reports are made publicly available 
for every entry. Simply put, what should be done with existing PDB entries found wanting 
by the validation procedures recommended herein? 
 
Workshop participants believe that the majority of Depositors would be motivated to 
correct entries identified as not meeting minimal standards for enhanced ligand 
validation. However, it was also recognized that, over time, increasing numbers of 
Depositors would not be in a position to make corrections. To ensure the integrity of the 
database, workshop participants propose that, following a reasonable interval for self-
correction, community experts could be mobilized to apply targeted corrections to any 
remaining PDB archival entries with poor validation outcomes, particularly for bound 
ligands of significant biological and/or medical interest.  
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Figure 
 
 
Figure 1.  Example highlighting the value of presenting ligand electron density model fit 
and geometrical analysis from CCDC Mogul from the Global Phasing Buster Report 
(PDB ID: 2H7P, later superseded by entry 4TZT (He et al., 2006); CCD ID: 468).   
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